Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMA/Sunbeam

This article was originally published in The Gray Sheet

Executive Summary

American Medical Association will pay Sunbeam $7.9 mil. in damages and $2 mil. for expenses under a settlement agreement announced July 31. The settlement resolves a September 1997 Sunbeam suit designed to hold AMA to the terms of a five-year marketing/educational agreement, which included the use of the AMA symbol on over-the-counter Sunbeam health care products in exchange for inclusion of AMA educational materials with the products ("The Gray Sheet" Sept. 15, 1997, In Brief). AMA put the agreement on hold after concerns were raised that the use of the association's symbol might be perceived as a product endorsement

You may also be interested in...



Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Nestlé Sees Importance Of Local Brands In ‘Fragmented’ VMS Market

As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.

Lupin Gets Another First With Fostair

Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.

UsernamePublicRestriction

Register

MT010451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel